BridgeBio looks set to challenge BioMarin’s monopoly in treating restricted growth in children with achondroplasia after generating promising Phase II data from its candidate infigratinib.
Approved in 2021, BioMarin’s Voxzogo (vosoritide) was the first therapy to help children with the dwarfism condition gain extra height, but the new infigratinib data suggests it is more
Key Takeaways
-
BridgeBio forecasts that its candidate could create a $2.5bn opportunity in achondroplasia, with the same again in hypochondroplasia
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?